Related Experiment Video
Updated: Jul 16, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report
G Schifitto1, D R Peterson, J Zhong
1Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. giovanni.schifitto@ctcc.rochester.edu
Abstract:
In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Antiepileptic Drugs: Glutamate Antagonists
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Alzheimer Disease l: Introduction
Hepatic Encephalopathy

